This document discusses Contract Research Organizations (CROs) and their role in supporting pharmaceutical clinical trials. It provides the following key points:
- CROs are service organizations that conduct clinical trials and other drug development work on behalf of pharmaceutical companies. They help companies that lack sufficient resources or expertise to conduct all required trials themselves.
- Selecting the right CRO is important for a successful clinical trial. Sponsors should clearly define study specifications, evaluate a CRO's capabilities and compatibility, and consider cost. Ongoing management of the sponsor-CRO relationship also impacts success.
- Common issues like selecting an inappropriate CRO, unclear study specifications from the sponsor, or poor management can lead
The Investigator's Brochure (IB) is a comprehensive document summarizing the body of information about an investigational product (IB) obtained during a drug trial.
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptxRAHUL PAL
The International Council on Harmonisation (ICH) defines an institutional review board (IRB) as a group formally designated to protect the rights, safety and well-being of humans involved in a clinical trial by reviewing all aspects of the trial and approving its startup. IRBs can also be called independent ethics committees (IECs).
An IRB/IEC reviews the appropriateness of the clinical trial protocol as well as the risks and benefits to study participants. It ensures that clinical trial participants are exposed to minimal risk in relation to any benefits that might result from the research.
IRB/IEC members should be collectively qualified to review the scientific, medical and ethical aspects of the trial.
Per the FDA, an IRB/IEC should have:
At least five members.
Members with varying backgrounds.
At least one member who represents a non-scientific area (a lay member).
At least one member who is not affiliated with the institution or the trial site (an independent member).
Competent members who are able to review and evaluate the science, medical aspects and ethics of the proposed trial.
This presentation gives a brief knowledge of CIOMS, its history, missions and collaborations of CIOMS. This presentation also contains CIOMS organizational structure, detailed knowledge of CIOMS Former and Present Working Groups. This will also guide about CIOMS form, its reporting and details to be filled while reporting an ADR.
The Investigator's Brochure (IB) is a comprehensive document summarizing the body of information about an investigational product (IB) obtained during a drug trial.
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptxRAHUL PAL
The International Council on Harmonisation (ICH) defines an institutional review board (IRB) as a group formally designated to protect the rights, safety and well-being of humans involved in a clinical trial by reviewing all aspects of the trial and approving its startup. IRBs can also be called independent ethics committees (IECs).
An IRB/IEC reviews the appropriateness of the clinical trial protocol as well as the risks and benefits to study participants. It ensures that clinical trial participants are exposed to minimal risk in relation to any benefits that might result from the research.
IRB/IEC members should be collectively qualified to review the scientific, medical and ethical aspects of the trial.
Per the FDA, an IRB/IEC should have:
At least five members.
Members with varying backgrounds.
At least one member who represents a non-scientific area (a lay member).
At least one member who is not affiliated with the institution or the trial site (an independent member).
Competent members who are able to review and evaluate the science, medical aspects and ethics of the proposed trial.
This presentation gives a brief knowledge of CIOMS, its history, missions and collaborations of CIOMS. This presentation also contains CIOMS organizational structure, detailed knowledge of CIOMS Former and Present Working Groups. This will also guide about CIOMS form, its reporting and details to be filled while reporting an ADR.
Organization and objectives of ICH, expedited reporting, ICSR, PSURs, post approval expedited reporting, pharmacovigilance Planning, good clinical practices
Clinical study on human subjects according to all guidelines to form a ideal protocol and requirement to conduct clinical trial with very efficient way mainly considering to India and ICH associated countries
For better understanding of students. This will give you a detailed explanation of IND APPLICATION. Contact me through comment section if you need any assistance in understating this topic.
Organization and objectives of ICH, expedited reporting, ICSR, PSURs, post approval expedited reporting, pharmacovigilance Planning, good clinical practices
Clinical study on human subjects according to all guidelines to form a ideal protocol and requirement to conduct clinical trial with very efficient way mainly considering to India and ICH associated countries
For better understanding of students. This will give you a detailed explanation of IND APPLICATION. Contact me through comment section if you need any assistance in understating this topic.
Understanding FDA Requirements Medical Devicesmarchell
The medical device market is experiencing explosive growth. Currently valued at $90 billion, market growth will continue to accelerate as demographics and market drivers increase their pressure for new and innovative product offerings.
Moreover, a substantial investment of time and resources is required to properly evaluate a new product idea and estimate its potential for success. So when a company executive declines a seemingly good product idea, what is probably being declined is the expense of properly evaluating the idea, and after having paid these expenses, the prospect of embarking on an expensive commercialization effort that has a 90 percent chance of failing.
TGA presentation: AusMedtech, 24 May 2017 TGA Australia
This presentation outlines reforms to the device regulatory system following the Expert Panel Review of Medicines and Medical Devices Regulation, reforms to the in vitro diagnostic devices (IVD) regulatory framework, reforms to the European and IVD system and the TGA's new Clinical Evidence Guidelines.
Regulatory Challenges with Outsourcing Clinical and Commercial Suppliesenarke
Pharma reliance in CRO’s is significant and growing
CRO’s differ in focus, strengths, and “personality”
Sponsor and CRO may see things differently, especially in early phases
CRO’s may tend toward being conservative and propose “belts and suspenders” to limit risk
Sponsors are often underequipped to manage progressive CMC across all phases
In sponsor’s interest to seek guidance for phase appropriate devel. & regul. posture
A positive and active sponsor – CRO relationship is invaluable and recommended
Ineffective sponsor-CRO relationship can produce friction and undesirable outcomes
Appealing top level bid dollars may mask significant other costs
Every new program is “from scratch” for the CRO “Don’t know what they don’t know”
CRO changes frequently occur: Information capture is vital for successful tech transfer
Sponsor diligence as to CRO regulatory patency is vital, especially in later phase
Outsourcing is a Cost-effective strategy when used properly and at present is gaining more and more importance. Here's a short presentation about the importance of outsourcing in Clinical research.
Uncovering Best Practices from Corporate Integrity AgreementsMD Ranger, Inc.
A CIA is a tool used by the OIG to address violations at healthcare organizations through policies and procedures designed to enforce compliance with regulations. A CIA is usually coupled with a civil settlement between the provider and the government to avoid exclusion from federal health programs.
In this presentation, we will discuss how to use recent CIAs to derive best practices that can benefit your organization.
We will cover:
-Common guidelines found in multiple CIAs
-Best practices from CIAs for specific types of healthcare entities
-Easy ways to improve your physician contracting compliance
-And more!
Best Practices for Successful Clinical Trials Approval in the Indian Market.pdfPranshuCorpseed
Clinical trials serve as the backbone of medical progress, shaping the landscape of
pharmaceutical innovation and ensuring the safety and efficacy of new treatments. In recent
years, India has emerged as a focal point for clinical research, offering a diverse patient
population and a robust healthcare infrastructure.
Best Practices and Points to Consider for Small-Medium Bio-Pharma CompaniesCovance
Small to medium sized companies face a host of unique challenges in the management of drug safety as they prepare to launch and sustain their products. Lack of clinical, safety and regulatory resources and expertise, along with inadequate technology infrastructure can create significant challenges and risks when advancing products through the life cycle. Find out how you can help your organizations overcome some common obstacles, learn from best practices and efficiently comply with global pharmacovigilance requirements.
Regulatory Challenges to Successful Global Clinical StudiesMichael Swit
A review of key issues that can make or break the success of a clinical study conducted outside the United States, with an emphasis on site, GCP issues, challenges that vary nationally, and enforcement concerns.
APM Benefits Summit 2017 : Realising benefits in a changing world
From ambition to delivery: Don't just do something, stand there and think!
presented by Joseph Lowe, HMRC
22 June 2017
Introduction types, Objectives, Management of audit, Responsibilities, Planni...Kunal10679
Audit and regulatory Compliance M.pharmacy Quality Assurance department Sem. 2 Introduction types, Objectives, Management of audit, Responsibilities, Planning Process, Information Gathering, Classifications of Deficiencies of auditing
Attending a job Interview for B1 and B2 Englsih learnersErika906060
It is a sample of an interview for a business english class for pre-intermediate and intermediate english students with emphasis on the speking ability.
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
Memorandum Of Association Constitution of Company.pptseri bangash
www.seribangash.com
A Memorandum of Association (MOA) is a legal document that outlines the fundamental principles and objectives upon which a company operates. It serves as the company's charter or constitution and defines the scope of its activities. Here's a detailed note on the MOA:
Contents of Memorandum of Association:
Name Clause: This clause states the name of the company, which should end with words like "Limited" or "Ltd." for a public limited company and "Private Limited" or "Pvt. Ltd." for a private limited company.
https://seribangash.com/article-of-association-is-legal-doc-of-company/
Registered Office Clause: It specifies the location where the company's registered office is situated. This office is where all official communications and notices are sent.
Objective Clause: This clause delineates the main objectives for which the company is formed. It's important to define these objectives clearly, as the company cannot undertake activities beyond those mentioned in this clause.
www.seribangash.com
Liability Clause: It outlines the extent of liability of the company's members. In the case of companies limited by shares, the liability of members is limited to the amount unpaid on their shares. For companies limited by guarantee, members' liability is limited to the amount they undertake to contribute if the company is wound up.
https://seribangash.com/promotors-is-person-conceived-formation-company/
Capital Clause: This clause specifies the authorized capital of the company, i.e., the maximum amount of share capital the company is authorized to issue. It also mentions the division of this capital into shares and their respective nominal value.
Association Clause: It simply states that the subscribers wish to form a company and agree to become members of it, in accordance with the terms of the MOA.
Importance of Memorandum of Association:
Legal Requirement: The MOA is a legal requirement for the formation of a company. It must be filed with the Registrar of Companies during the incorporation process.
Constitutional Document: It serves as the company's constitutional document, defining its scope, powers, and limitations.
Protection of Members: It protects the interests of the company's members by clearly defining the objectives and limiting their liability.
External Communication: It provides clarity to external parties, such as investors, creditors, and regulatory authorities, regarding the company's objectives and powers.
https://seribangash.com/difference-public-and-private-company-law/
Binding Authority: The company and its members are bound by the provisions of the MOA. Any action taken beyond its scope may be considered ultra vires (beyond the powers) of the company and therefore void.
Amendment of MOA:
While the MOA lays down the company's fundamental principles, it is not entirely immutable. It can be amended, but only under specific circumstances and in compliance with legal procedures. Amendments typically require shareholder
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
Unveiling the Secrets How Does Generative AI Work.pdfSam H
At its core, generative artificial intelligence relies on the concept of generative models, which serve as engines that churn out entirely new data resembling their training data. It is like a sculptor who has studied so many forms found in nature and then uses this knowledge to create sculptures from his imagination that have never been seen before anywhere else. If taken to cyberspace, gans work almost the same way.
Improving profitability for small businessBen Wann
In this comprehensive presentation, we will explore strategies and practical tips for enhancing profitability in small businesses. Tailored to meet the unique challenges faced by small enterprises, this session covers various aspects that directly impact the bottom line. Attendees will learn how to optimize operational efficiency, manage expenses, and increase revenue through innovative marketing and customer engagement techniques.
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
What are the main advantages of using HR recruiter services.pdfHumanResourceDimensi1
HR recruiter services offer top talents to companies according to their specific needs. They handle all recruitment tasks from job posting to onboarding and help companies concentrate on their business growth. With their expertise and years of experience, they streamline the hiring process and save time and resources for the company.
Accpac to QuickBooks Conversion Navigating the Transition with Online Account...PaulBryant58
This article provides a comprehensive guide on how to
effectively manage the convert Accpac to QuickBooks , with a particular focus on utilizing online accounting services to streamline the process.
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...BBPMedia1
Grote partijen zijn al een tijdje onderweg met retail media. Ondertussen worden in dit domein ook de kansen zichtbaar voor andere spelers in de markt. Maar met die kansen ontstaan ook vragen: Zelf retail media worden of erop adverteren? In welke fase van de funnel past het en hoe integreer je het in een mediaplan? Wat is nu precies het verschil met marketplaces en Programmatic ads? In dit half uur beslechten we de dilemma's en krijg je antwoorden op wanneer het voor jou tijd is om de volgende stap te zetten.
2. INTRODUCTION
• A Contract Research Organization (CRO) is a service
organization which provides support to the pharmaceutical
industry.
• It offers various pharmaceutical research that is essential for
conducting clinical trials in the present boom, when various
complications are involved in the drug discovery process.
• Various companies are involved in his type of development many
examples are the like Lupin , Quintil, Cipla, Zydus, Cadeila.
• They are also conduct these type of trails with the
collaboration of many multinational companies and these
Indian companies are making space in foreign.
2
3. BACKGROUND
• There is a growing reliance by sponsors on contracting out part or
all of the work of the clinical trial to a sub-contractor.
• Manufacturers often find that they cannot organize every clinical
trial that they require.
The reasons are many, but commonly reflect;
• limited staff resources
• pressures of time.
• Subsequently, the field has expanded to include firms in the areas of;
– formulation development
– stability programs
– pharmacokinetic studies
– biostatistics
– data management
3
4. An Overview of CROs
• Traditionally, a CRO was viewed by pharmaceutical industry
something as;
• an un-acceptable risk, because of
• lack of confidence in it terms of their qualification, experience and
capabilities.
• However, the modern view is that the in- house staff can be kept
for “core needs” e.g.,
• designing of study
• selection of CRO.
• A list of qualified CROs is developed based on;
– The sponsors needs
– The range of services provided by CRO
– The therapeutic area of expertise of CRO, and
– The compatibility with the sponsor 4
5. MARKET STRUCTURE OF CRO
Top 10 CROs-75%Revenue
Avg revenue /company $1.3
ue
5
Top 10 CROs-75%Revenue
Avg revenue /company $1.3
billion
Next 10 CROs -11% revenue
Avg revenue/company-$220
Million
Niche segment 14% revenue
Avg Revenue /company-$3.1
Million
6. WHEN TO USE A CRO?
• Strategies for using CROs typically fall into three categories:
– Tactical outsourcing
– Maximal outsourcing
– Strategic outsourcing
Tactical Outsourcing
• Individual studies or selected activities within a study are
contracted to a CRO only when in-house resources become
inadequate because of an unfore-seen study or a reduction in staff.
Maximum Outsourcing
• With this strategy the sponsor outsources nearly all of its clinical
development activities to CROs.
Strategic Outsourcing
• The sponsor conducts Phase I and early Phase II studies, and hires
CROs to conduct larger and routine studies.
6
7. FREQUENT CAUSES OF
SPONSOR/CRO PROBLEM
• Problems with contract studies can often be traced by;
– The wrong CRO is selected.
– Sponsors often make the mistake of assuming that a CRO that
has performed well on one study will be equally capable of
conducting a study in a different therapeutic area.
Some sponsors mistakenly assume that all CROs are the same.
– The sponsor fails to articulate its needs clearly.
– Sponsors sometimes issue a request for proposal (RFP) with
little more than a protocol outline, and expect CROs to guess
what services and resources are required.
7
8. • In order to ensure successful outsourcing, the sponsor should focus
on three critical steps:
– Determine accurate study specifications
– Select the right CRO
– Manage the study
THREE CRITICAL STEPS TO
ENSURE SUCCESS WITH A CRO
8
9. DETERMINE STUDY
SPECIFICATIONS
• Study specifications are a list of activities required to initiate,
conduct, analyze, and report the results of a clinical study.
• They include tasks that will be performed in-house and those to be
contracted out to one or more CROs.
Importance of Accurate Study Specifications
• Study specifications are an essential element of the sponsor’s
request for proposal (RFP) and the CRO’s proposal.
• Accurate study specifications also enable the CRO to perform a
‘reality check’ on the sponsor’s expectations.
• This analysis also provides useful criteria for selecting the right
CRO.
9
10. SELECTING THE RIGHT CRO
• The three most important criteria for selecting a CRO are:
– Capability
– Compatibility
– Cost
MANAGING THE SPONSOR-CRO RELATIONSHIP
• The sponsor should follow three principles for managing an
outsources project:
– Clarify the role and responsibilities of the sponsor and CRO.
– Define and use ‘performance metrics’ to measure study
progress.
– Ensure efficient communication between the sponsor and
CRO.
10
11. Sponsor Roles and Responsibilities
– Define the study specifications
– Provide information to the CRO
– Monitor results
– Recognize ‘red flags’
– Resolve problems
– Approve changes in ‘scope’
11
12. CRO Roles and Responsibility
• If the sponsor has provided detailed study specifications and the
CRO is experienced in the target therapeutic area, it will be
possible for the CRO to;
• compare its past experiences with the sponsor’s projections.
• CRO roles and responsibilities are…
– Evaluate feasibility
– Provide adequate, well managed staff
– Conduct study activities
– Manage processes
– Bring problems and proposed solutions to the sponsor’s
attention
– Ensure that the solutions are cost-effective
12
13. Performance Metrics
• Their validity is established by demonstrating that they are related
to achieving quality, ensuring timelines, and managing cost.
• Performance metrics should be negotiated between the sponsor and
CRO prior to the study.
• When performance metrics demonstrate that the CRO is failing to
meet the objectives, the sponsor and CRO have a shared
responsibility to examine the process and agree on an appropriate
solution.
• Most interactions between the sponsor and the CRO will take place
between the individual team members and their technical counter-
parts.
• Discussions between sponsor and CRO technical staff should focus
on information exchange and issue identification.
13
14. Sponsor-CRO Study Initiation Meeting
• The sponsor and CRO teams should hold a ‘kick-off’ meeting prior
to initiation of the study.
• The goals of the meeting are:
– To promote ownership of the study among team members
– To clarify the roles and responsibilities of the sponsor and CRO
– To identify the primary sponsor and CRO contacts
– To present the agreed to performance metrics and audit
procedures
– To define the approach to problem resolution
– To define those changes that can be agreed upon informally and
those that require a formal change order
14
15. • They should be identified at an early stage, so that they have
minimal impact on study cost, timing, and quality.
• It is important for a team member to inform the project manager of
any issue before attempting to resolve it.
• This information will enable the project manager to determine;
– whether the problem is an isolated case.
– is part of a larger problem that needs to be addressed with the
corresponding project manager.
IDENTIFYING AND RESOLVING
PROBLEMS
15
16. Ten ‘Red Flags’
• Red flags are early warning that may not require immediate action,
but should be evaluated to determine whether a significant
underlying problem exists.
• Each team member may wish to prepare a list of red flags for
his/her individual technical area.
Typical red flags and the possible significant underlying problems
are:
– Selection of in-experienced investigators by the CRO: the CRO
monitoring staff may be inexperienced .
– Questions from the study site directed to the sponsor: the CRO
may not have provided adequate training to site personnel.
– In-adequate monitoring reports from the CRO: the CRO
monitoring staff may not be receiving adequate training and
supervision. 16
17. CONTRACT RESEARCH
Legal Background
• The arrangements made for the conduct of clinical research will
usually give rise to a number of legal contracts.
• For example, there will be a contract between a sponsor and any
appointed clinical research organization (CRO); between the
sponsor or CRO and the investigator or the institution in which the
investigator works.
• It would be unusual to have a contract between a patient participant
and the sponsor or investigator, although this may arise where the
participant is a private patient of the investigator.
17
18. • In contracts relating to clinical research between a sponsor, CRO or
investigator/institution much of the detailed provisions concerning
precisely how the research will be conducted will be contained in
the trial protocol.
• There is no prescribed format for clinical research contracts.
• A standard form must always be adapted to fit the particular study.
• However, the following are a non-exhaustive checklist of points
that might be considered for inclusion in a contract.
18
19. Study details
• The protocol should be incorporated by reference into the
contract
• The protocol must not be deviated from, except;
1. As agreed in writing between the parties and approved by the
ethics committee.
2. In the opinion of the investigator, it is necessary to do so
immediately in order to protect the health and safety of a
research subject.
• A ‘key person’ clause should be considered. This might specify
that identified individuals, or a certain number of staff specified
minimum qualifications, will work on the study.
• The contract should address whether the CRO or investigator is
allowed to subcontract any of their obligations and, if so, which
of them.
19
20. Compliance
• A specified party must hold or obtain (and maintain) all necessary
authorizations.
• All legal and regulatory requirements (including labeling) must be
complied with.
• Compliance with the ICH,Good Clinical Practice Guidelines or
equivalent should be required.
• The investigator must obtain ethical approval from relevant ethics
committees before beginning the study and refer all amendments.
• The study must be carried out to the highest professional standards.
20
21. Timing
• Start date, duration/end date should be identified.
• The number of subjects to be recruited by specified dates should be
addressed.
• The options if the recruitment rate is not on target.
• Provision for making status reports, providing interim analysis
reports and submitting the final report by specified date should be
made.
21
22. Data
• Except for the purposes of the study and as required by law, the
data must be kept confidential.
• Retention of title by specified parties (in particular the sponsor) in
identified documents and materials should spelled out.
• Protection of intellectual property rights of the sponsor must be
covered.
• Arrangements for maintaining safety and security of data,
documents and trial supplies should be identified.
• The investigator will maintain all records relating to the study,
including case report forms, for as long as is practicable.
• Responsibility and procedure for notification of Adverse Drug
Reactions (ADRs) or other unexpected or unusual occurrences in
compliance with the legislation needs to be described.
22
23. Payment
The contract should specify:
• The amounts and timing (advance, stage or interim and final) of
payments and the payment of reasonable expenses.
• Whether separate accounts are to be established.
• Provision for alteration of budget in the event of amendment of the
protocol, or extent of services to be provided, and early
termination.
Materials
• Supply of the investigator brochure, updates, product and
documentation by sponsor.
23
24. Product Liability
• In relation to liability issues, the contract should cover:
1. Indemnity to be provided by the sponsor for any liability
costs and expenses of the investigator arising out of personal
injury claims, subject to conditions.
2. Indemnity by the CRO or investigator in favor of the sponsor
in respect of negligence, breach of contract by the CRO or
investigator.
3. Observance of applicable local guidelines
4. Financial provision for handling of claims (e.g., insurance
arrangements).
24
25. Termination
• Appropriate provision for termination, especially early
termination, is essential:
1. On specified grounds; sensible to provide for termination by
the sponsor on notice without reason, but subject to the
obligation to pay for work done at that point.
2. The rights of termination, if any, consequent upon a breach of
contract by either party should be described.
3. Termination upon the insolvency, administration or
liquidation of either party, or long-term suspension of the
agreement (i.e. circumstances beyond the control of either
party) should be addressed.
25
26. CONCLUSION
• More effective contracting of clinical drug-development activities
to CROs can be achieved by applying the following methods:
– Use a strategic approach to outsourcing
– Follow the three principles for achieving success with CROs:
define accurate study specifications; select the right CRO; and
manage the study.
– Select CROs according to the three Cs: capability, compatibility
and cost.
– Evaluate the CRO’s resource allocations
– Define the performance metrics
– Ensure efficient communication with CRO
26